CoChat

Sitagliptin and pancreatic cancer risk in patients with type 2 diabetes

Tseng, Chin‐Hsiao · 2016 · European Journal of Clinical Investigation
Cited by 39

The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.

Abstract

Background: The risk of pancreatic cancer associated with incretin‐based therapies is controversial. Methods: This study retrospectively analysed the National Health Insurance database including patients with newly diagnosed type 2 diabetes mellitus at an age ≥ 25 years between 1999 and 2010. A total of 71 137 ever users of sitagliptin and 933 046 never users were followed for pancreatic cancer until 31 December 2011. A time‐dependent approach was used to calculate incidence and estimate hazard ratios adjusted for propensity score using Cox regression. Results: During follow‐up, 83 ever users and 3658 never users developed pancreatic cancer, representing an incidence of 73·6 and 55·0 per 100 000 person‐years, respectively. The adjusted hazard ratio (95% confidence intervals) for ever versus never users was 1·40 (1·13–1·75). The respective adjusted hazard ratio for the first, second and third tertile of cumulative dose < 14 700, 14 700–33 700 and > 33 700 mg was 1·83 (1·28–2·62), 1·97 (1·41–2·76) and 0·72 (0·45–1·15). For average daily dose of < 50, 50–99·9 and ≥ 100 mg, the respective hazard ratio was 3·10 (1·17–8·26), 1·01 (0·63–1·61) and 1·53 (1·18–1·97). Conclusions: Sitagliptin is significantly associated with a higher risk of pancreatic cancer, especially when the cumulative dose is < 33 700 mg. The risk diminished in users with a higher cumulative dose. The daily dose of sitagliptin should better be kept < 100 mg, and its use should be reconsidered in patients who suffer from severe renal impairment and thus a daily dose of < 50 mg is always recommended. Future studies are required to confirm the findings with more appropriate adjustment for smoking.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/eci.12570

Cites

5 of 5 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 39

Metadata

Authors
Tseng, C.
Venue
European Journal of Clinical Investigation
Publisher
Wiley
Published
2015-12-17
Volume
46
Issue
1
Pages
70-79
ISSN
  • 0014-2972 (ISSN-L)
  • 1365-2362
OpenAlex
W2172304980
Cited by
39
References
5
FWCI
2.73
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.